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1. Introduction
Neurodevelopmental disorders, sometimes referred to as disorders of intellectual disability
(ID), are a large family of conditions of genetic, acquired, or environmental origin that are
characterized by deficiencies in cognitive and behavioral functions. While many of these dis‐
orders share similar behavioral phenotypes, they are often accompanied with other features
specific to each disorder. One disorder with a unique progression is Rett Syndrome (RTT;
Online Mendelian Inheritance in Man #312750; http://www.ncbi.nlm.nih.gov/omim/). RTT is
the leading cause of severe ID in females, with approximately 1:10,000 females worldwide
affected by this disorder. Mutations in the gene encoding the transcriptional regulator,
methyl-CpG-binding protein 2 (MeCP2), located on the X chromosome (Xq28), have been
confirmed in more than 95% of individuals meeting diagnostic criteria for RTT. RTT is char‐
acterized by an uneventful early infancy followed by stagnation and regression of growth,
motor, language, and social skills later in development.
RTT was first described by Dr. Andreas Rett, an Austrian developmental pediatrician in the
1960’s, and was also recognized about the same time by Dr. Bengt Hagberg, a Swedish child
neurologist. Dr. Rett was the first to publish initial cases on a number of girls that he was fol‐
lowing in his practice that had the same repetitive hand-washing motion with a similar neuro‐
developmental  phenotype  (Rett  1966).  Dr.  Rett  initially  described  this  disorder  as  an
association with increased ammonia levels, but it was latter discovered that this characteriza‐
tion was incorrect due to an improperly calibrated measurement system. These observations
and subsequent characterization by Dr. Rett would go unnoticed by the broader medical com‐
munity in large part related to the publication of the manuscript in a German-language medi‐
cal journal. A chance meeting of Hagberg and Rett in 1981 in Toronto led to the first widely read
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English language publication by Hagberg and colleagues from France and Portugal that attrib‐
uted the disorder to Rett’s early work. Thus, it was not until 1983, in an English-language medi‐
cal journal, that Bengt Hagberg and colleagues reported 35 females that had a similar disease
progression; onset around 7 to 18 months of age, with developmental stagnation followed by
rapid worsening of numerous neurological functions (Hagberg, Aicardi et al. 1983).
RTT is typically diagnosed early in the life of a female and based on strict diagnostic criteria
that have been extensively established (Neul, Kaufmann et al. 2010); (Percy, Neul et al. 2010).
These criteria are based on the unique disease progression, which begins with stalled develop‐
mental progress after an apparently normal pregnancy and an uneventful first 6–18 months of
life. After development becomes abruptly stagnated, frank regression occurs in growth, mo‐
tor, language, and social skills that leads to either partial or complete loss of these skills. The
next period of RTT consists of stabilization and recovery of socialization skills by age four to
five that persist into adulthood. While the research into pathology and genetics of RTT has
made great strides from Dr. Rett’s initially characterization, a number of things have stayed
constant. First, RTT is still an observational disorder; certain hallmark features that differenti‐
ate this  disorder from other neurodevelopmental  disorders.  Second,  RTT has no cure at
present and treatment is based on health issues that are specific for each person.
2. Clinical features
The general overview of this disorder from a clinical perspective is a disease associated with
phenotypes that vary depending on the age of the child. The developmental profile is a dis‐
tinct feature of RTT that includes three unique stages. The first stage is an apparently nor‐
mal gestational period and a generally ordinary period of development typically occuring
until approximately 6-18 months of age. The next developmental period may last up to 4
years of age, characterized first by the stagnation of development and then the frank regres‐
sion in growth, motor, language, and social skills (Percy 2002). This is the most detrimental
period in the progression of the disorder with the prominent loss, partial or complete, of
cognitive, social, and motor skills. The last period of RTT consists of stabilization and recov‐
ery of socialization skills by age four to five with persistence into adulthood. Due in part to
better clinical understanding and immense effort that has been put forth to study this disor‐
der, recent projections predict that individuals with RTT will live into adult life with aver‐
age survival just over age 50 (Kirby, Lane et al. 2010).
In most individuals with RTT, the single, most observable and characteristic feature consists
of stereotypic hand movements. These stereotypies, of yet unknown neurological origin,
may consist of hand washing, wringing, squeezing, clapping, tapping, or rubbing and are
evident in approximately 94% of individuals (figure 1) (Percy and Lane 2005), (Carter,
Downs et al. 2010). Furthermore, they are continuous during waking hours; only subsiding
when the individual falls asleep. Another motor difficulty that these individuals display is
difficulty maintaining balance and ambulation. Most girls walk at some point in their life
(~80%), however gait and balance issues arise, presumably from poor motor control and sig‐
nificant anxiety, such that about 25% lose this ability.
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Figure 1. Image of two females with Rett Syndrome, displaying stereotypical hand behavior
Behavioral issues, in addition to cognitive and social regression, are another hallmark of
RTT. Heightened anxiety and mood disturbances are well-known features in many girls
with RTT, and demonstrated by behaviors including difficulties maintaining posture and
breathing irregularities (Mount, Charman et al.  2002; Robertson, Hall et al.  2006). RTT is
considered an Autism Spectrum Disorder (ASD) due in part to the girls being withdrawn
from  social  contact,  thus  demonstrating  communication  dysfunction  (Percy  2011).  It  is
during this period of regression that features consistent with autism emerge. They often
lack the ability to respond to commands and lose the ability for verbal  communication.
For this reason, RTT is commonly compared to autism. However, the autistic features are
generally  transient  in  RTT,  typically  subsiding after  the  age of  three-four  years.  At  this
time  point,  while  language  acquisition  might  not  ever  occur,  eye  gaze  returns  and  be‐
comes the primary form of communication with the outside world. It is believed that the
description of RTT as an autistic disorder and the ability to develop non-verbal communi‐
cation could be used as a diagnostic sign.
3. Diagnostic criteria
RTT is diagnosed based on observable criteria. While MeCP2 mutation occurs in an over‐
whelming majority of individuals diagnosed with RTT, positive mutations of the gene are
not part of the diagnostic checklist, but as a supporting piece of information. In 2009 investi‐
gators from the RettSearch Consortium, an international group of clinicians and researchers
revised the diagnostic criteria in order to clarify and simplify the diagnosis of classic (typi‐
cal) and variant (atypical) forms (Neul, Kaufmann et al. 2010). Listed in table 1 is the set of
definitive diagnostic criteria for classic RTT.
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Inclusion and exclusion criteria for diagnosis of classic RTT
Period of developmental regression
Period of recovery or stabilization
Evidence of all main criteria
1. Partial or complete loss of acquired purposeful hand skills
2. Partial or complete loss of spoken language
3. Gait Abnormalities
4. Stereotypic hand movements
5. Exclusion of brain injury secondary to trauma or grossly abnormal psychomotor development in
first 6 months of life
Table 1. Consensus criteria for the diagnosis of classic RTT
Additionally analysis  of  the RTT population through the many years of  following these
individuals  in  clinics  throughout  the  world  have  noted  a  wide  variability  in  severity
where individuals might present with some, but not all clinical features that would signi‐
fy  a  diagnosis  of  classical  RTT.  For  this  reason,  a  number  of  recognized atypical  forms
have  been  characterized  and  documented  based  on  unique  characteristics  (Neul,  Kauf‐
mann  et  al.  2010).  The  atypical  forms  that  have  been  established  consist  of  preserved
speech, early seizure, and congenital variants (Hagberg and Skjeldal 1994). The RettSearch
Consortium provided consensus criteria and core features essential for diagnosis of atypi‐
cal forms of RTT (table 2).
Diagnosis of atypical forms of RTT
Period of developmental regression followed by period of stabilization
Meet at least 2 of 4 phenotypes from the main criteria
Meet at least 5 of 11 supportive criteria
Supportive Criteria
1. Abnormal muscle tone
2. Breathing disturbances when awake
3. Bruxism
4. Diminished response to pain
5. Growth retardation
6. Impaired sleep pattern
7. Inappropriate laughing or screaming spells
8. Intense eye communication
9.Peripheral vasomotor disturbances
10. Scoliosis/kyphosis
11. Small/cold hand and feet
Table 2. Consensus criteria and core features essential for diagnosis of atypical forms of RTT; preserved speech, early
seizure, and congenital variants
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4. Physical features and pathophysiology
From an initial observation, individuals with RTT tend to be very small in terms of height
for their age, nearly 2-3 standard deviations from normal (Hagberg, Stenbom et al. 2001).
Furthermore, a deceleration of the rate of height and weight is also a characteristic of this
disease (Schultz, Glaze et al. 1993). Given that individuals with RTT tend to be very small, it
is no surprise that their feet and hand growth are also often stunted.
Many studies have been conducted that have examined head size and brain growth. Head
circumference in RTT individuals is also very small for their age and head growth decelera‐
tion occurs as early as 1.5 months of age (Tarquinio, Motil et al. 2012 in press). Similar to
body height, head circumference was also found to be 2-3 standard deviations below values
estimated in healthly individuals (Hagberg, Stenbom et al. 2001). Furthermore, RTT brains
typically weigh less than those from unaffected individuals (Armstrong 2005). Microscopic
studies of brains from autopsy samples have demonstrated that neurons from numerous
cortical areas, including the hippocampus and thalamus, are smaller in size and densely
packed, without evidence of neurodegeneration or gliosis (Bauman, Kemper et al. 1995;
(Armstrong 2005).
It has long been suggested that disorders related to ID have been associated with structural
irregularities in neuronal connectivity (Fiala, Spacek et al. 2002) (Kaufmann and Moser
2000). This well supported notion was developed from pioneering studies in the 1970’s that
described striking abnormalities in the dendritic morphology of cortical neurons obtained
from postmortem brain samples from individuals with a number of different disorders asso‐
ciated with ID (Huttenlocher 1970; Marin-Padilla 1972; Huttenlocher 1974; Purpura 1974).
From this standpoint, a number of studies have been conducted that provide evidence to
suggest that reduced or altered neuronal connectivity at synapses is a characteristic of RTT.
To support this notion, magnetic resonance imaging demonstrated a reduction in gray mat‐
ter volume in the parietal lobe in addition to reductions in cortical white matter (Bauman,
Kemper et al. 1995; Carter, Lanham et al. 2008). Consistent with these findings, dendritic
growth and arborization are reduced in RTT (Belichenko, Oldfors et al. 1994; Armstrong,
Dunn et al. 1995; Chapleau, Calfa et al. 2009).
Another fascinating discovery that was uncovered during these series of observations from
the 1970’s was the description of alterations in dendritic spines on the postsynaptic side of
excitatory synapses. Postmortem observations described reductions in dendritic spine densi‐
ties in addition to changes in their shape, commonly referred to as “spine dysgenesis” (Pur‐
pura 1974). Confocal imaging studies using postmortem brains from individuals diagnosed
with RTT or control individuals, have demonstrated a decrease in the density of dendritic
spines in several areas of the brains including the somatosensory cortex and hippocampus
(Belichenko, Oldfors et al. 1994; Armstrong, Dunn et al. 1995; Chapleau, Calfa et al. 2009).
Molecular analysis of postmortem brains further supports this notion, as studies have found
that the expression of microtubule-associated protein (MAP-2), a protein involved in micro‐
tubule stabilization and a key cytoskeletal component of dendrites, is reduced in the cortex
of RTT individuals (Kaufmann, Naidu et al. 1995; Kaufmann, Taylor et al. 1997). Further‐
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more, expression levels of cyclooxygenase, a protein enriched in dendritic spines is also re‐
duced in RTT cortex (Kaufmann and Moser 2000). With regard to density of synapses,
reduced levels of the synaptic vesicle protein, synaptophysin, were detected in the motor,
frontal and temporal cortices by immunofluorescence (Belichenko, Hagberg et al. 1997). In‐
triguingly, glutamate receptor density has a differential distribution during RTT develop‐
ment, where younger individuals with RTT have a higher density compared to controls,
while older individuals have a lower density compared to controls (Blue, Naidu et al. 1999).
These results suggest that an increase in glutamate receptor density may be a compensation
for the reduction in dendritic spines.
In addition to these various anatomical brain findings, a number of alterations have been
discovered in its neurochemistry. Specific areas of the brain including the midbrain and cau‐
date, which produce a number of neurotransmitters, have been shown to have reduced vol‐
ume compared to healthy individuals (Reiss, Faruque et al. 1993). In support of this finding,
tyrosine hydroxylase staining was reduced in the substantia nigra, an important region for
dopamine production (Jellinger, Armstrong et al. 1988). Furthermore, cerebrospinal fluid
(CSF) measurements of RTT individuals, demonstrated a reduction in the dopamine metab‐
olite, homovanillic acid, and the serotonin metabolite, 5-hydroxyindoleacetic acid (Samaco,
Mandel-Brehm et al. 2009).
A number of other structural and physical abnormities have been demonstrated. One strik‐
ing physical finding can be made upon observation and by touching an individual’s feet. In
many individuals with RTT, feet are not only cold to touch, but may appear blue or purplish
in color. It is assumed that defective autonomic function is the pathological culprit; however
the exact mechanism for this has yet to be determined. Another finding that might relate to
dysfunction in autonomic signaling is abnormal cardiac conduction. A feature that has been
observed in a number of individuals diagnosed with RTT is a prolonged QT interval, where
the timing between ventricle depolarization and repolarization is delayed, which is estimat‐
ed to occur in approximately 20% of individuals (McCauley, Wang et al. 2011) (Sekul, Moak
et al. 1994). For this reason, at the time of the diagnosis of RTT (and every one to two years
thereafter), one of the first tests to be ordered is an electrocardiogram (EKG), in order to
guard against the sudden death risk with prolonged QT intervals.
Another condition that arises in the RTT population, presumably because of altered meta‐
bolic requirements, lack of physical mobility, and their small stature, is osteopenia, a con‐
dition characterized by reduced bone mineralization and increased likelihood of fractures
(Haas, Dixon et al. 1997). Reduced bone size and lower bone mass have been detected in
the RTT population (Roende, Ravn et al. 2011). Lastly, irregularities in the motility of the
gastric  region and esophageal  tract  lead to  the development of  gastroesophageal  reflux,
which is a major cause of pain and discomfort (Motil, Schultz et al. 1999). Abnormalities
in gallbladder function, in addition to the accumulation of gallstones, have been identified
as a serious concern in the RTT population and may require surgical  assessment (Percy
and Lane 2005).
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5. Genetics and MeCP2
A number of clinical observations linked this disorder to a genetic mutation of de novo ori‐
gin. First, RTT predominantly affected female individuals; second, RTT rarely recurred in
the same family, and third, RTT was a worldwide disorder that affected all racial and ethnic
groups, not commonly associated with a pattern of inheritance. In the 1990’s after much ear‐
ly speculation, numerous studies determined that RTT was indeed caused by a genetic mu‐
tation. First, mapping studies using RTT families mapped the mutation to the X
chromosome with subsequent analyses localizing the likely gene at Xq28, confirming an X-
linked dominant pattern of inheritance (Archidiacono, Lerone et al. 1991; Ellison, Fill et al.
1992; Sirianni, Naidu et al. 1998). After this lengthy study of the X chromosome, a hallmark
paper was published in 1999 identifying the gene encoding methyl-CpG-binding protein 2
(MECP2) (Amir, Van den Veyver et al. 1999).
More than 95% of individuals with classic RTT carry a de novo  mutation in the gene en‐
coding MECP2.  To date, more than 250 different mutations of MECP2  have been identi‐
fied in the RTT population, with about 60% of the mutations coming from 8 specific point
mutations  involving  the  following  amino  acid  changes  (R106W,  R133C,  T158M,  R168X,
R255X, R270X, R294X, R306C) (Williamson and Christodoulou 2006). Interestingly, muta‐
tions on MECP2  have only been identified in approximately ~75% of atypical or variant
RTT (Percy, Lane et al. 2007). Characterizations of MECP2 mutations through genetic test‐
ing provide molecular confirmation of the diagnosis of RTT but should not be used as the
sole diagnostic factor, as roughly 5% of the classical RTT population do not have defined
mutations of MeCP2, but meet the clinical criteria (Neul, Fang et al. 2008). While the rea‐
son that the MECP2 gene is susceptible to mutations is not understood, the overwhelming
majority of RTT cases are a result of spontaneous de novo MECP2 mutations in the pater‐
nal X chromosome germlines (Trappe, Laccone et al. 2001). However, some families do ex‐
ist  where  MECP2  mutations  are  present  throughout  multiple  generations  (Augenstein,
Lane et al. 2009).
MeCP2,  a  member  of  the  methyl-CpG-binding  domain  (MBD)  family  of  transcriptional
regulator  proteins,  is  encoded by  a  ~76kb  gene  located  on  chromosome Xq28  and con‐
structed  from  four  exons  associated  with  two  protein  isoforms,  MECP2_e1  and
MECP2_e2. The MeCP2 protein has two major functional domains; the methyl-binding do‐
main (MBD),  consisting of 85 amino acids that  binds specifically to DNA at methylated
CpG's, and the transitional repressing domain (TRD), consisting of 104 amino acids, that
is responsible for recruiting other proteins to form complexes that mediate transcription of
various genes (Guy, Cheval et al. 2011). MeCP2 binds specifically to A/T rich sites in close
proximity to CpG-methylated DNA sites, working with other proteins in recruiting co-re‐
pressors  and  histone  deacetylase  complexes,  thereby  altering  the  structure  of  genomic
DNA and modifying the transcription of specific target genes (Klose and Bird 2006). Re‐
cent studies have demonstrated that MeCP2 has both repressor and activator transcription
activities  (Chahrour,  Jung  et  al.  2008).  MeCP2  has  been  shown  to  be  tightly  bound  to
DNA at all times and its transcriptional control activity is regulated by post-translational
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modifications  such  as  phosphorylation  and  acetylation,  that  alter  the  conformational
shape of DNA, enabling or repressing transcription of a potential target gene (Skene, Il‐
lingworth et  al.  2010;  Cohen,  Gabel  et  al.  2011).  Furthermore,  a  role  of  MeCP2 in RNA
splicing has also been hypothesized due to  its  ability  to  interact  with the RNA-binding
protein, Y box-binding protein (Young, Hong et al. 2005).
6. MeCP2 function
The  precise  mechanism  of  dysfunction  of  mutated  MeCP2  that  is  responsible  for  RTT
symptomatology remains unknown. MeCP2 is highly expressed in the brain and is critical
for the development and maturation of neurons (Akbarian, Chen et al. 2001);,(Jung, Jugl‐
off et al. 2003);,(Mullaney, Johnston et al. 2004). Recent reports suggest that the MeCP2 is
also expressed in glial cells and altered function of glial cells might be another reason for
disease progression (Ballas, Lioy et al. 2009);,(Maezawa, Swanberg et al. 2009);,(Maezawa
and Jin 2010). Expression of MeCP2 in humans and mice increases with neuronal develop‐
ment  and  maturation  (Shahbazian  et  al.,  2002).  In  addition,  the  expression  levels  of
MeCP2  control  the  development  of  excitatory  synapses  early  in  postnatal  development
(Chao, Zoghbi et al. 2007). Since MeCP2 expression in cortical areas increases during neu‐
ronal development, it is assumed that MeCP2 is crucial for axonal and dendritic differen‐
tiation  during  the  first  6–18  months  of  age  leading  to  proper  synapse  formation  and
maturation. Furthermore, new data suggests that MeCP2 expression is also important in
adulthood, as MeCP2 removal during later stages of postnatal/adult development, altered
the density of excitatory synapses and the expression of synaptic proteins involved with
maintaining synapses (Nguyen, Du et al. 2012).
The functions of MeCP2 have been shown to extend beyond its importance in the develop‐
ment and maintainence of synapses in the brain. It has been shown that MeCP2 regulates
the balance between excitatory and inhibitory transmission. It is unknown exactly how
MeCP2 governs the balance between glutamate and GABA, but recent studies suggest that
altered MeCP2 might also be expressed on non-neuronal brain cells (i.e., oligodendroglia
and astrocytes) that regulate the uptake of glutamate (Maezawa and Jin 2010). Astrocytes
from mutant Mecp2 mice co-cultured with wild-type neurons caused significant dendritic
damage to the neurons. In support of these findings, recent studies using hippocampal slices
from mecp2 mutant mice demonstrate these tissues to be extremely hyperexcitable (Calfa,
Hablitz et al. 2011). Furthermore, studies in null mice demonstrated that GABAergic synap‐
tic transmission is weakened in the ventrolateral medulla region of the brain stem (Chao,
Chen et al. 2010).
Another important finding related to MeCP2 function relates to the concept of homeostatic
plasticity, a type of plasticity whereby an optimal level of transmission is regulated by mod‐
ulating the strength of excitatory and inhibitory synapses. Recent evidence has demonstrat‐
ed that MeCP2 functions in synaptic scaling, a form of homeostatic plasticity that regulates
the strength of excitatory synapse currents in response to neuronal activity (Qiu, Sylwestrak
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et al. 2012). These data suggest that MeCP2 is involved with balancing network excitability.
Since glutamate levels tend to be increased in individuals with RTT, in addition to the com‐
mon occurrence of seizures (Glaze, Percy et al. 2010), mechanisms responsible for modulat‐
ing glutamate transmission or increasing GABAergic transmission need to be explored as a
treatment option.
7. Disease severity
As we discussed previously, wide variability in phenotypic severity is observed in RTT.
Since the gene for MeCP2 resides on the X-chromosome, the balance of X-chromosome inac‐
tivation (XCI) plays an important factor in disease severity. Studies have shown that indi‐
viduals with classical RTT have XCI that has a random distribution, whereas nonrandom
XCI is associated with milder phenotypes (Amir, Van den Veyver et al. 2000). However, a
dramatic example of the importance of XCI in RTT comes from a family in which the same
MECP2 mutation was present in several family members (Augenstein, Lane et al. 2009). The
mother, had a 44bp mutation, passed the mutation to a daughter with classical RTT and a
son with a progressive neurological disorder. The mother, who had some cognitive deficits,
does not have any features of RTT and has an XCI ratio that favors the “good” X-chromo‐
some (89:11).
In addition to XCI, another factor to consider is the genotype-phenotype relationship. Vari‐
ous mutations or types of mutation tend to be associated with different phenotypes. For the
most part, nonsense mutations, mutations that cause a premature stop transcription, tend to
produce more severe effects than missense mutations. For instance, the R133C mutation is
associated with a less severe phenotype compared to the R168X mutation, one of the most
severe mutations as individuals tend not to walk, use hands, or speak (Neul, Fang et al.
2008). Furthermore, missense mutations in the TRD tend to have a milder phenotype (Scha‐
nen, Houwink et al. 2004).
8. Treatment options
Therapeutic management for these individuals can be quite complicated when taking into
account their specific neurodevelopmental phenotype. Research into the clinical manage‐
ment of RTT relies on focusing on present day treatment using FDA approved agents and
future research using newly found molecules. Moreover, the present day treatment research
focuses on reviewing the entire spectrum of symptoms that relate to RTT, while future treat‐
ment options focus on discovering molecules that could cure the entire disorder. Conduct‐
ing clinical trials in this population is challenging as stratification of participants requires
careful planning. Additionally as a result of the difficulty in performing clinical trials in
these individuals, few results have come from previous clinical trials that have provided un‐
questionable therapeutic recommendations. An issue in performing studies in the RTT pop‐
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ulation is the huge variability in disease severity, which makes comparison between groups
an extremely challenging task. Trials using the drug naltrexone to blocked the observed in‐
crease in beta-endorphin expression, appeared to diminish motor behavior overall (Budden,
Myer et al. 1990) (Percy, Glaze et al. 1994). Other clinical trials have been conducted in the
RTT population to examine the potential effectiveness of the vitamin, folate, on disease pro‐
gression. Results from the study demonstrated no major improvement in objective measure‐
ments (Glaze, Percy et al. 2009).
Numerous strategies to cure RTT have been proposed that are based on preclinical evalua‐
tion of potential pharmacological agents or based on the proposed mechanism of MeCP2
dysfunction. One issue to address in treatment options is to determine if a specific point in
development exists where treatment has to be initiated to rescue function. Studies have
shown symptom resolution can be accomplished in MeCP2 null transgenic mice by simply
turning on the expression of MeCP2 in adult mice. Using an insertion of the lox-stop cassette
into the Mecp2 gene of mice, where tamoxifen administration removed the stop cassette
causing Mecp2 expression to be activated fully, symptomatic mice were noted to have mark‐
edly diminished severity of RTT-like phenotypes. (Guy, Gan et al. 2007).
These studies suggest that for a potential curative agent, therapy could be initiated at any time
point in development and lead to potential benefit. Potential therapies that could be developed
stem from these basic properties of MeCP2. The first option revolves around the lifespan of mu‐
tant proteins. Transgenic mice were created with a mutation in the methyl binding domain of
the MeCP2 protein (T158A), causing a reduction in MeCP2 binding affinity to methylated
DNA and reducing the protein’s half-life (Goffin, Allen et al. 2011). Thus a potential therapeu‐
tic option is to increase either the protein’s expression or half-life, granted that mutant MeCP2
proteins do not lead to a gain of function deficit. Another potential therapy relates to the loca‐
tion of the MECP2 gene and the modulation of XCI. When XCI is randomly distributed in RTT,
individuals tend to be more severely affected compared to situations of nonrandom XCI where
a greater percentage of cells express the normal allele (Amir, Van den Veyver et al. 2000). By
taking advantage of this process, if the normal allele is turned on and the mutate allele is turned
off, it is possible that symptom improvement would occur. In an overwhelming majority of in‐
stances, de novo MECP2 mutations have been identified in the paternal X chromosome (Trappe,
Laccone et al. 2001). If this is the case, by identifying the locus of the mutation, a practical ap‐
proach could be developed to turn off the mutant allele and activate the normal allele. This is a
technically challenging, but potentially exciting strategy.
Another potential therapy that revolves around modulating the existing genetic environ‐
ment is by using a molecule that allows read-through of premature STOP codons in mutant
genes. Nonsense mutation in MECP2 resulting in premature transcription termination oc‐
curs in approximately 35% of North American RTT patients (Percy, Lane et al. 2007). Ami‐
noglycosides are antibiotics that are used today against resistant gram-negative bacteria, but
studies have shown that they also have potential as pharmacological agents to overcome
transcriptional termination caused by nonsense mutations (Rowe and Clancy 2009),(Zing‐
man, Park et al. 2007). In various models, the full-length MeCP2 protein was discovered in
different cell cultures expressing nonsense mutations after incubation with an aminoglyco‐
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side antibiotic. (Brendel, Klahold et al. 2009),(Brendel, Belakhov et al. 2011),(Popescu, Sidor‐
ova et al. 2010). From a functional standpoint, iPSC-derived neurons from RTT patients
expressing nonsense mutations, when treatment with the aminoglycoside gentamicin was
employed, demonstrated increased dendritic spine density (Marchetto, Carromeu et al.
2010). While a potentially useful molecule has yet to be tested in transgenic mouse express‐
ing a nonsense MeCP2 protein, this particular approach might be of great promise for this
subset of the RTT population.
Another option revolves around the use of the growth factor, BDNF, a member of the neuro‐
trophin family of growth factors that have essential roles in neuronal survival and differen‐
tiation in early development and a strong modulator of synaptic transmission and plasticity
in the mature brain (Amaral, Chapleau et al. 2007). BDNF protein levels measured by ELISA
were found to be lower in brain samples of Mecp2 mutant mice (Chang, Khare et al. 2006).
Intriguingly, crossbreeding Bdnf heterozygous mice with Mecp2 mutant mice exacerbated
the onset of the RTT-associated phenotypes.(Chang, Khare et al. 2006) More importantly,
BDNF mRNA levels are lower in brain samples from RTT patients, similar to the finding de‐
scribed in MeCP2 mutant mice (Deng, Matagne et al. 2007).
Promising work has shown that the genetic overexpression of BDNF can rescue some of the
deleterious consequences of MeCP2 dysfunction. For example, crossbreeding Bdnf overex‐
pressing mice with Mecp2 mutants alleviated numerous phenotypes, including motor hypo‐
activity, reduced activity of cortical neurons, in addition to extending their lifespan (Chang,
Khare et al. 2006) Consistently, BDNF overexpression in neurons transfected with RTT-asso‐
ciated MECP2 mutations or with Mecp2 shRNA to knockdown its expression reversed den‐
dritic atrophy in primary hippocampal neuron cultures (Larimore, Chapleau et al. 2009).
While the genetic overexpression of BDNF is promising in rodent models, the administra‐
tion of BDNF is not a useful clinical approach due to its short half-life and inability to cross
the blood–brain barrier.(Kingwell 2010) However, small molecules that can mimic BDNF’s
effects or that can increase the levels of endogenous BDNF are attractive potential therapeu‐
tic options. Small molecules that act like BDNF, so called “BDNF mimetics,” are blood-brain
barrier permeable factors and have shown promise to reverse RTT-like features in experi‐
mental mouse models. Heterozygous female mecp2 mutant mice, treated with LM22A-4, res‐
cued breathing abnormalities and increased TrkB phosphorylation in areas of the brain
central for respiration, medulla and pons.(Schmid, Yang et al. 2012) 7,8-DHF delayed body
mass deficits and improved wheel running and breathing impairments in mutant male
mice.(Johnson, Lam et al. 2011) While these agents present limited supporting research, they
do offer hope of targeting BDNF without administering the actual protein.
Another potential option that has recently gained much attention as therapeutic treatment of
RTT individuals is the pleiotropic growth factor insulin-like growth factor-1 (IGF-1). Unlike
BDNF, IGF-1 crosses the blood-brain barrier and gains access to the CNS. IGF-1 stimulates
proliferation of neural progenitors, neuronal survival, neurite outgrowth, and synapse for‐
mation (D'Ercole, Ye et al. 1996),(D'Ercole, Ye et al. 2002). Consistent with these BDNF mim‐
etic actions, daily injections of the active tri-peptide fragment of IGF-1 improved motor
function, breathing rhythm and cardiac irregularities, in addition to increased brain weight
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in Mecp2 mutant mice (Tropea, Giacometti et al. 2009). The active tri-peptide also improved
a number of synaptic features, including dendritic spine density in pyramidal neurons of
layer V of the motor cortex. In the same region of the cerebral cortex, IGF-1 restored the mo‐
tility of dendritic spines, a process crucial for synaptic development and plasticity (Landi,
Putignano et al. 2011). Since the full-length IGF-1 is approved by the Food and Drug Admin‐
istration for the treatment of growth failure in children that were unresponsive to treatment
with growth hormone,(Fintini, Brufani et al. 2009) a clinical trial is currently underway to
determine if administration of Mecasermin (Increlex®), a synthetic analog of full-length
IGF-1 improves the symptoms and health of RTT patients (ClinicalTrials.gov identifier:
NCT01253317).
9. Conclusions
It should also be noted that other genes have been linked to variant RTT, including cyclin-
dependent kinase-like 5 (CDKL5), FOXG1, and the Netrin G1 genes. Future research exam‐
ining MeCP2 dysfunction needs to consider the influence of MeCP2 mutations on other
disorders.
The greatest challenge at present is to develop translational research that implements
unique options developed at the basic science level and moves them efficiently and smooth‐
ly to the clinical setting. Furthermore, since many common neurobiological mechanisms ex‐
ist in the spectrum of neurodevelopmental disorders, understanding the key components
might hasten the progress of novel treatment for all these unique and devastating disorders.
As the clinical and basic science understanding of RTT has unfolded, key points of interac‐
tion have been targeted to approach its understanding and potential management. From the
clinical perspective, the array of medical issues includes epilepsy, periodic breathing, altered
growth patterns, gastrointestinal dysfunction, and significant orthopedic issues including
scoliosis. From the basic science viewpoint, the epigenetic role of MECP2, with emphasis on
known elements such as brain derived neurotrophic factor and corticotrophin releasing hor‐
mone, and the broad impact on neural function have led to exciting opportunities for thera‐
peutic intervention currently receiving intense scrutiny at the translational level at the same
time that clinical investigation and intervention, particularly related to augmentative com‐
munication strategies are increasing. Future research regarding the treatment of RTT must
rely on determining which dysregulated genes contribute to a specific symptom or symp‐
tom cluster, and what drug therapy might overcome this dysfunction.
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